PMC:7228307 / 15940-16631 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"318","span":{"begin":324,"end":331},"obj":"Gene"},{"id":"319","span":{"begin":445,"end":452},"obj":"Gene"},{"id":"320","span":{"begin":25,"end":29},"obj":"Gene"},{"id":"321","span":{"begin":0,"end":7},"obj":"Gene"},{"id":"322","span":{"begin":139,"end":145},"obj":"Species"},{"id":"323","span":{"begin":431,"end":438},"obj":"Gene"}],"attributes":[{"id":"A318","pred":"tao:has_database_id","subj":"318","obj":"Gene:2213"},{"id":"A319","pred":"tao:has_database_id","subj":"319","obj":"Gene:9103"},{"id":"A320","pred":"tao:has_database_id","subj":"320","obj":"Gene:2213"},{"id":"A321","pred":"tao:has_database_id","subj":"321","obj":"Gene:9103"},{"id":"A322","pred":"tao:has_database_id","subj":"322","obj":"Tax:9606"},{"id":"A323","pred":"tao:has_database_id","subj":"323","obj":"Gene:2212"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa. Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals. Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T165","span":{"begin":67,"end":77},"obj":"Body_part"},{"id":"T166","span":{"begin":215,"end":220},"obj":"Body_part"},{"id":"T167","span":{"begin":241,"end":245},"obj":"Body_part"},{"id":"T168","span":{"begin":379,"end":390},"obj":"Body_part"}],"attributes":[{"id":"A165","pred":"fma_id","subj":"T165","obj":"http://purl.org/sig/ont/fma/fma82740"},{"id":"A166","pred":"fma_id","subj":"T166","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A167","pred":"fma_id","subj":"T167","obj":"http://purl.org/sig/ont/fma/fma74402"},{"id":"A168","pred":"fma_id","subj":"T168","obj":"http://purl.org/sig/ont/fma/fma66835"}],"text":"FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa. Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals. Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T7","span":{"begin":391,"end":395},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0002415"}],"text":"FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa. Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals. Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T293","span":{"begin":0,"end":2},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T294","span":{"begin":14,"end":24},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T295","span":{"begin":25,"end":27},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T296","span":{"begin":139,"end":145},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T297","span":{"begin":213,"end":220},"obj":"http://purl.obolibrary.org/obo/CL_0000236"},{"id":"T298","span":{"begin":221,"end":223},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T299","span":{"begin":227,"end":230},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T300","span":{"begin":241,"end":245},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T301","span":{"begin":324,"end":326},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T302","span":{"begin":391,"end":395},"obj":"http://purl.obolibrary.org/obo/UBERON_0002415"},{"id":"T303","span":{"begin":411,"end":421},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T304","span":{"begin":431,"end":433},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T305","span":{"begin":445,"end":447},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T306","span":{"begin":475,"end":485},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T307","span":{"begin":515,"end":516},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T308","span":{"begin":634,"end":641},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa. Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals. Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T79","span":{"begin":67,"end":77},"obj":"Chemical"}],"attributes":[{"id":"A79","pred":"chebi_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/CHEBI_36976"}],"text":"FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa. Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals. Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T98","span":{"begin":215,"end":220},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa. Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals. Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T12","span":{"begin":67,"end":77},"obj":"Chemical"}],"attributes":[{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_36976"}],"text":"FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa. Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals. Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"318","span":{"begin":324,"end":331},"obj":"Gene"},{"id":"319","span":{"begin":445,"end":452},"obj":"Gene"},{"id":"320","span":{"begin":25,"end":29},"obj":"Gene"},{"id":"322","span":{"begin":139,"end":145},"obj":"Species"},{"id":"323","span":{"begin":431,"end":438},"obj":"Gene"}],"attributes":[{"id":"A318","pred":"pubann:denotes","subj":"318","obj":"Gene:2213"},{"id":"A319","pred":"pubann:denotes","subj":"319","obj":"Gene:9103"},{"id":"A320","pred":"pubann:denotes","subj":"320","obj":"Gene:2213"},{"id":"A322","pred":"pubann:denotes","subj":"322","obj":"Tax:9606"},{"id":"A323","pred":"pubann:denotes","subj":"323","obj":"Gene:2212"}],"text":"FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa. Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals. Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T22","span":{"begin":139,"end":145},"obj":"Species"}],"attributes":[{"id":"A22","pred":"ncbi_taxonomy_id","subj":"T22","obj":"NCBItxid:9605"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa. Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals. Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T99","span":{"begin":0,"end":439},"obj":"Sentence"},{"id":"T100","span":{"begin":440,"end":558},"obj":"Sentence"},{"id":"T101","span":{"begin":559,"end":691},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa. Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals. Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this."}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T7","span":{"begin":391,"end":395},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0002415"}],"text":"FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa. Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals. Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T164","span":{"begin":67,"end":77},"obj":"Body_part"},{"id":"T165","span":{"begin":215,"end":220},"obj":"Body_part"},{"id":"T166","span":{"begin":241,"end":245},"obj":"Body_part"},{"id":"T167","span":{"begin":379,"end":390},"obj":"Body_part"}],"attributes":[{"id":"A164","pred":"fma_id","subj":"T164","obj":"http://purl.org/sig/ont/fma/fma82740"},{"id":"A165","pred":"fma_id","subj":"T165","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A166","pred":"fma_id","subj":"T166","obj":"http://purl.org/sig/ont/fma/fma74402"},{"id":"A167","pred":"fma_id","subj":"T167","obj":"http://purl.org/sig/ont/fma/fma66835"}],"text":"FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa. Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals. Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this."}

{"project":"LitCovid-sentences","denotations":[{"id":"T99","span":{"begin":0,"end":439},"obj":"Sentence"},{"id":"T100","span":{"begin":440,"end":558},"obj":"Sentence"},{"id":"T101","span":{"begin":559,"end":691},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa. Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals. Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this."}